GSK 2696274

Drug Profile

GSK 2696274

Alternative Names: ARSA gene therapy - GlaxoSmithKline/Fondazione Telethon/Ospedale San Raffaele; ARSA transduced autologous CD34+ stem cells - GlaxoSmithKline/Fondazione Telethon/Ospedale San Raffaele; Arylsulfatase A gene therapy -GlaxoSmithKline/Fondazione Telethon/Ospedale San Raffaele; Ex vivo stem cell gene therapy - GlaxoSmithKline/Fondazione Telethon/Ospedale San Raffaele; GSK2696274

Latest Information Update: 03 Sep 2015

Price : $50

At a glance

  • Originator Fondazione Telethon; GlaxoSmithKline; Ospedale San Raffaele
  • Class Gene therapies; Stem cell therapies
  • Mechanism of Action Gene expression stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Metachromatic leukodystrophy
  • New Molecular Entity No

Highest Development Phases

  • Phase II Metachromatic leukodystrophy

Most Recent Events

  • 29 Jul 2015 Phase-II clinical trials in Metachromatic leukodystrophy (In children, In infants) in Italy (IV)
  • 20 Apr 2015 GlaxoSmithKline, Fondazione Telethon and Ospedale San Raffaele complete enrolment in phase I/II trial for Metachromatic leukodystrophy (In infants, In children) in Italy (NCT01560182)
  • 01 Apr 2010 Phase-I/II clinical trials in Metachromatic leukodystrophy (In infants, In children) in Italy (IV) (NCT01560182))
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top